Home Clinical Research Current Clinical Trails A Phase I，Multicenter, Open-Label, Dose Escalation Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, ICP-022, in Patients with Relapsed/Refractory B-Cell Malignancies

ICP CL 00107

Condition: Patients with histologically confirmed B-cell malignancies including r/r FL, r/r MZL and CLL/SLL with/without prior treatment. | Last Updated: | Status:

View Full Study